Effects of the ergot alkaloids dihydroergotamine, ergonovine, and ergotamine on growth of Escherichia coli O157:H7 in vitro.

A series of experiments were conducted to evaluate the effects of ergot alkaloids (dihydroergotamine, ergonovine, and ergotamine) on E. coli O157:H7 in both pure and mixed ruminal fluid culture. Alkaloids were added to solutions of E. coli O157:H7 strains 933 (pure and ruminal cultures) and 6058 (ruminal culture only), and growth rates and colony-forming units (CFU) of E. coli O157:H7 were measured. Two mixtures of all three alkaloids at either 2 or 500 microM for each alkaloid decreased (p < 0.001) the growth rate of E. coli O157:H7 in pure culture compared to the individual alkaloids. Dihydroergotamine tended (p = 0.07) to reduce growth rate of E. coli O157:H7 in pure culture compared with ergonovine or ergotamine alone. Increased concentrations of dihydroergotamine and ergotamine decreased (p < 0.003) growth rate of E. coli O157:H7 but increasing concentrations of ergonovine did not influence (p > 0.10) E. coli O157:H7 growth rate. Similar to results in pure culture, a mixture of all three alkaloids at various concentrations for each alkaloid decreased (p < 0.001) the CFU of E. coli O157:H7 strain 6058 in mixed ruminal culture compared to the individual ergot alkaloids. Dihydroergotamine decreased (p = 0.04) CFU of E. coli O157:H7 strain 6058 when compared to ergonovine but CFU were similar (p > 0.10) between dihydroergotamine and ergotamine. Ruminal and (or) intestinal populations of E. coli O157:H7 may be influenced in livestock consuming endophyte-infected tall fescue, and these alterations could be due to the presence of ergot alkaloids in fescue plants.

Modulation of cytochrome P450 metabolism by ergonovine and dihydroergotamine.

This study investigated modulation of the cytochrome P450 3A (CYP3A4)-mediated metabolism of ergotamine (ET) by ergonovine and dihydroergotamine. Liver microsomes were prepared from rats treated i.p. for 4 d with: low (10 mM) or high (100 mM) levels of dexamethasone (DM10 and DM100), dihydroergotamine, ergonovine, or control. Cytochrome P450 activity was evaluated using ET and its isomers as substrate. Ergotamine was converted to its metabolites at rates of 0.385 or 0.535 (SE = 0.040) nM/microg protein/min when incubated with liver microsomes from DM10 or DM100 treated rats, respectively. These rates were higher than for rats on other treatments. Induction of CYP34A activity was not greater for ergonovine or dihydroergotamine treatments than for controls. Both ergonovine and dihydroergotamine treatments inhibited in vitro CYP3A4 activity in a dose dependent manner producing quadratic inhibition curves.

Hepatic metabolism of ergot alkaloids in beef cattle by cytochrome P450.

This study was conducted to investigate the involvement of cytochrome P450 3A (CYP3A) in the metabolism of ergotamine in beef liver microsomes. When incubated with liver microsomes, ergotamine was hydroxylated to metabolites M1 and M2. Similarly, its isomer was hydroxylated to M1-Iso and M2-Iso (8-hydroxy-derivatives). Further incubation resulted in a second hydroxylation of M1 and M2 to metabolites M3 and M4 (8,9-dihydroxy derivatives). Maximum formation of metabolites was reached after 20 min, and ergotamine and its isomer were almost totally metabolized after 60 min of incubation. The formation of these metabolites was completely dependent on the presence of NADPH or the NADPH generating system and was also dependent on microsome concentration. Ergotamine was converted at a rate of 2 nM/microgram microsome/min when incubated with bovine liver microsomes to produce a metabolite profile (M1, M2, M1-Iso and M2-Iso) similar to the metabolites produced (2.2 nM/microgram/min) when ergotamine was incubated with liver microsomes of dexamethasone treated rats. This work provides information on the modification of ergotamine in bovine liver microsomes by CYP3A, which is of importance in understanding the detoxification and the clearance of ergotamine and other ergot alkaloids by bovine.

The interaction of thioridazine with cardiac cytochrome oxidase; enzyme activity and drug binding studies.

Thioridazine interacts with purified cardiac cytochrome oxidase altering both the activity of the enzyme and the optical spectrum of the drug. Cytochrome oxidase activity, as measured by oxidation of cytochrome c, exhibits a biphasic response to changing drug concentration. Lower concentrations of thioridazine increased cytochrome oxidase activity up to 20% at 65 microM and higher concentrations inhibit activity until almost complete inhibition is observed. Both the activation and the inhibition of cytochrome oxidase by thioridazine follow Michaelis-Menton kinetics with Vmax changing but Km remaining constant. The analysis of the 2 nm shift in the UV absorption spectrum of the thioridazine suggest that the binding of thioridazine to cytochrome oxidase involves multiple (535) binding sites on the enzyme with an average dissociation constant of 20 microM.